arrow
E

Emilio Alba

University Hospital Virgen de la Victoria
H指数:53
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Whole-genome sequencing of Reed-Sternberg cells identifies outcome determinants in Hodgkin lymphoma

对里德-斯泰伯格细胞的基因组测序确定了霍奇金淋巴瘤的预后决定因素

2026-09-040
OA
Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer

早期乳腺癌中微小残留病灶检测和复发监测的双ctDNA和CTCs分析

2026-05-200
OAAI
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: the PHENOMENAL phase 2 study

脂质体伊立替康在HER2阴性乳腺癌和脑转移患者中的应用:PHENOMENAL II期研究

2025-12-040
PRE
Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy

新辅助化疗后三阴性乳腺癌辅助卡培他滨的真实世界数据分析

2025-11-180
OAAI
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study

Zanidatamab联合palbociclib和fulvestrant治疗既往接受过治疗的激素受体阳性、HER2阳性转移性乳腺癌:一项两阶段、多中心、单臂、2a期研究的主要结果

2025-05-050
PRE
Gestational breast cancer: distinctive molecular and clinico-epidemiological features
2024-11-081
OAAI
Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review
2024-08-010
OAAI
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients
2024-05-151
OAAI
Primary results from a phase 2a study of zanidatamab (zani) plus palbociclib (palbo) plus fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)
2024-05-020
PRE
Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the GEICAM/2013-02 (PEARL) trial
2024-05-020
PRE
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
2024-01-035
OAAI